Page 16 - Manjri Chandak News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Manjri chandak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Manjri Chandak Today - Breaking & Trending Today

Five dead in Serum fire, new launches likely to be hit: CEO Poonawalla


Five people were killed on Thursday in a major fire that broke out in a Serum Institute of India factory, but the world’s largest vaccine maker said the incident would not affect the production of Covid-19 vaccine even as new launches may be hit.
Sparks from welding work being carried out in the under-installation factory in Pune had triggered the fire that destroyed some floors of the building, local authorities said. Maharashtra Health Minister Rajesh Tope said an investigation and a fire audit will be done.
Prime Minister Narendra Modi expressed anguish over the incident. “In this sad hour, my thoughts are with the families of those who lost their lives. I pray that those injured recover at the earliest,” he tweeted. ....

Ajit Pawar , Narendra Modi , Amitabh Gupta , Adar Poonawalla , Maharashtra Health , Pune City Police , Serum Institute Of India , Serum Institute , Health Minister Rajesh Tope , Minister Narendra Modi , Chief Executive Officer Adar Poonawalla , அஜித் பவார் , நரேந்திர மோடி , அமிதாப் குப்தா , அடார் பூனாவல்ல , மகாராஷ்டிரா ஆரோக்கியம் , புனே நகரம் போலீஸ் , சீரம் நிறுவனம் ஆஃப் இந்தியா , சீரம் நிறுவனம் , ஆரோக்கியம் அமைச்சர் ராஜேஷ் தோப்பே , அமைச்சர் நரேந்திர மோடி , தலைமை நிர்வாகி அதிகாரி அடார் பூனாவல்ல ,

Serum Institute Of India And Dynavax Announce First Participants Dosed In The Phase 1/2 Clinical Trial For A COVID-19 Vaccine


Share this article
Share this article
PUNE, India and EMERYVILLE, Calif., Dec. 23, 2020 /PRNewswire/  Further strengthening its fight against COVID-19, Serum Institute of India (SIIPL), the world s largest vaccine manufacturer by volume, has partnered with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing novel vaccines, and today jointly announced that the first participants have been dosed in the Phase 1 part of the Phase 1/2 clinical trial evaluating SIIPL s vaccine candidate adjuvanted with CpG 1018 to prevent COVID-19.
The Phase 1/2 clinical trial will evaluate the safety and immunogenicity of SIIPL s vaccine candidate consisting of the SARS-COV-2 virus receptor binding domain (RBD) delivered as a virus-like particle (VPL), along with Dynavax s advanced adjuvant CpG 1018 plus alum. The Phase 1 portion of the clinical trial will enroll 39 healthy volunteers and post the completion of the study ....

Derek Cole , Ryan Spencer , Nicole Arndt , Adar Poonawalla , Mayank Sen , Exchange Commission , Serum Institute Of India Pvt Ltd , Investor Relations Advisory Solutions , Drug Administration , Serum Institute Of India , Dynavax Technologies Corporation Nasdaq , Serum Institute , Dynavax Technologies Corporation , Chief Executive Officer , India Pvt , Annual Report , Senior Manager , டெரெக் கோல் , ரியான் ஸ்பென்சர் , நிக்கோல் அரண்டட் , அடார் பூனாவல்ல , மயங்க் சென் , பரிமாற்றம் தரகு , சீரம் நிறுவனம் ஆஃப் இந்தியா பிரைவேட் லிமிடெட் , சீரம் நிறுவனம் ஆஃப் இந்தியா , சீரம் நிறுவனம் ,

Codagenix and Serum Institute of India Announce Commencement of First-in-Human Trial of COVI-VAC, A Single Dose, Intranasal Live Attenuated Vaccine for COVID-19


Share this article
Share this article
NEW YORK and PUNE, India, Dec. 14, 2020 /PRNewswire/ Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) today announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK. COVI-VAC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19, that was shown to be safe and efficacious in preclinical animal studies. COVI-VAC was developed with Codagenix s Synthetic Attenuated Virus Engineering (
SAVE) platform that uses synthetic biology to re-code the genes of viruses into safe and stable vaccines. COVI-VAC is designed to deliver a safe, live attenuated version of SARS-CoV-2 that may induce a more robust immune response and long-lasting cellular immunity against SARS-CoV-2 compared to other vaccines against the virus. ....

United Kingdom , City Of , Johanna Bennett Ingrid Mezo , Steffen Mueller , Mayank Sen , J Robert Coleman , Eckard Wimmer At Stony Brook University , Prnewswire Codagenix Inc , Serum Institute Of India Pvt , National Academy Of Science , Healthcare Products Regulatory Agency , Serum Institute Of India , Codagenix Inc , Serum Institute , Synthetic Attenuated Virus Engineering , Rajeev Dhere , Executive Director , National Academy , Eckard Wimmer , Stony Brook University , Adjuvant Capital , Topspin Partners , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஸ்டெஃபென் முல்லர் , மயங்க் சென் ,